Protocolo diagnóstico de la cardiopatía en el paciente oncológico

In patients with cancer who are going to undergo oncologic treatment, cardiovascular risk factors and pre-existing heart disease must be identified and considered before starting therapies associated with potential cardiovascular toxicity. Based on this assessment, a prevention and follow-up plan must be established to enable an early diagnosis and manage cardiovascular complications. The risk-benefit ratio of certain oncologic treatments will be evaluated by multidisciplinary teams, determining whether to continue or discontinue therapy in the presence of adverse events. In patients undergoing prolonged treatment with high cardiovascular risk, follow-up must be performed until the end of treatment. Upon completion of oncologic therapy, a reassessment of cardiovascular risk is recommended with a focus on coordinating long-term follow-up to detect potential late complications. In the case of secondary neoplasms, the patient's cardiovascular risk must always be restratified before initiating any treatment.